Flavonoids as Prospective Aromatase Inhibitors in Breast Cancer Preven-tion/Therapy

Flavonoids have been shown to target aromatase, suppressing the transformed cells' pro-liferation and growth. Such experimental data further promoted the usage of flavonoids as an aromatase inhibitor and helps prevent cancer, specifically breast and lung cancer. Conversely, flavonoids have certain limitations like low absorption, potency, and some side effects in addition to their tremendous advantages. The pharmacokinetics and toxicity of flavonoids are now being ad-dressed by using advanced nanotechnological approaches. This review discusses the comprehen-sive aromatase signaling pathway in normal and cancer cells. It also draws attention to how do flavonoids modulate aromatase signaling pathways. Also, different flavonoid groups inhibiting aro-matase activities are discussed and listed in the Table comprising flavonoids group, cancer type, clinical trials, IC50, and the assay employed. Moreover, nanoparticles-mediated improvement in the pharmacokinetics and toxicity issues of flavonoids in targeting aromatase are also deliberated. In conclusion, flavonoids act as a potential anticancer agentvia targeting aromatase. Besides, nan-otechnological approaches are useful in addressing the pharmacokinetics and toxicity flavonoids.

Automated summary

Flavonoids act as potential anticancer agents by targeting aromatase to inhibit the growth of transformed cells. However, they have limitations such as low absorption and potential side effects, which are being addressed through advanced nanotechnological approaches. This review also discusses how flavonoids modulate aromatase signaling pathways and the use of nanoparticles to improve their pharmacokinetics and toxicity in targeting aromatase.